Kunming Institute of Zoology, Chinese Academy of Sciences, acquires GLP certification from the CFDA

The Center for Drug Safety Evaluation from the Kunming Institute of Zoology (KIZ) acquired Good Laboratory Practice (GLP) Certification from the China Food and Drug Administration (CFDA) on June 30, 2015. This is the second pre-clinical safety evaluation organization to have obtained GLP Certification in the Yunnan Province and within the Chinese Academy of Sciences, and is also the first GLP center to have qualification for toxicokinetics testing in Yunnan.

In the 1950s, KIZ established the first nonhuman primate artificial domestication and breeding center in China. In 2008, it became the first organization in Yunnan and within the Chinese Academy of Sciences to obtain certification from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), and currently houses some 5,000 nonhuman primates, including rhesus monkeys, machin monkeys and tree shrews. In recent years, the KIZ has made considerable progress and achievement in nonhuman primate models of major human diseases, including HIV, diabetes, Alzheimer's disease, learning-memory, mother-baby separation, morphine-addiction, breast cancer, and tristimania. In addition, the KIZ has developed many hemostasis, analgesia, anti-thrombus, anti-infection, antioxidant, and anti-neoplastic prodrugs, and obtained new drug approval documents from the CFDA.

The Center for Drug Safety Evaluation was established in 2012, and was structured to include complete quality management systems and enhanced software and hardware levels based on the “Kunming National Biological Industrialization Base, Experimental Animal Center” of the National Development and Reform Commission. The center has engaged in drug pharmacology and toxicology studies using nonhuman primates, and has accumulated significant experience in GLP and non-GLP tests.

With GLP Certification, the KIZ will develop a complete new drug research technology chain, and provide a convenient, efficient and reliable technology platform for new drug research and pre-clinical safety evaluation for the Chinese Academy of Sciences and medical industry. The KIZ will also fulfil a significant role in promoting independent research and development of innovative drugs, and undertake major national projects and social services for the Chinese Academy of Sciences and Yunnan Province.